<DOC>
	<DOC>NCT00077883</DOC>
	<brief_summary>The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.</brief_summary>
	<brief_title>TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 years of age or older Histologically confirmed nonsmall cell lung cancer Stage IV or IIIB Measurable disease by RECIST ECOG performance status of 01 Adequate liver and renal function Adequate bone marrow reserve History of bone marrow transplantation or stem cell support Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>